Crinetics Pharmaceuticals (CRNX) Misses Q3 EPS by 13c
Tweet
Share
E-mailGet Alerts CRNX Hot Sheet
Join SI Premium – FREE
Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q3 EPS of ($1.38), $0.13 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $143 thousand versus the consensus estimate of $491 thousand.
For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SLM (SLM) Misses Q2 EPS by 16c; offers guidance
- First Resource Bank (FRSB) Tops Q2 EPS by 92c
- Alpine Income Property Trust, Inc. (PINE) Tops Q2 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
